Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer

Published on September 20, 2021

The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.

Continue reading on website
Other news

PRA Group (PRAA) Declares Pricing of Senior Notes Offering

September 20, 2021
To boost financial flexibility, PRAA Group (PRAA) prices senior notes to procure funds and pay back its outstanding revolving borrowings under the Nor...

Casey's (CASY) Digital Efforts Augur Well for Customer Wins

September 20, 2021
Casey's (CASY) efforts to boost online and delivery capabilities are enriching customer experience and expanding its sales.